AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29382957 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram treatment (level 1 treatment)
Number of subjects: 2280
Study 29383572 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (30, 50 or 70 mg/day) for 104 weeks
Number of subjects: 314
Study 29383680 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency surgery
Number of subjects: 0
Study 29383782 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) completely withdrawn
Number of subjects: 36
Study 29383782 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) stepped-down to a reduced dose
Number of subjects: 36
Study 29383782 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline predictors of failure to stop ICS
Number of subjects: 36
Study 29383782 — intervention group
Group type: EXPERIMENTAL
Intervention: After first step-down of ICS
Number of subjects: 36
Study 29384473 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-related processes
Number of subjects: 0
Study 29384473 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of MEG and fMRI data
Number of subjects: 0
Study 29384721 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic staging imaging within 30 days of locoregional recurrence
Number of subjects: 445
Study 29384721 — intervention group
Group type: EXPERIMENTAL
Intervention: Locoregional recurrence types (lymph node, postmastectomy chest wall, in-breast)
Number of subjects: 445
Study 29384721 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial presenting stage
Number of subjects: 445
Study 29384721 — intervention group
Group type: EXPERIMENTAL
Intervention: Locoregional recurrence type
Number of subjects: 445
Study 29384721 — intervention group
Group type: EXPERIMENTAL
Intervention: Insurance status
Number of subjects: 445
Study 29384927 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin
Number of subjects: 68
Study 29385166 — intervention group
Group type: EXPERIMENTAL
Intervention: Locomotor training (LT) on a treadmill using body-weight support for 80 daily one-hour sessions
Number of subjects: 8
Study 29385166 — intervention group
Group type: COMPARATOR
Intervention: Usual care (non-trained; regular at-home routine)
Number of subjects: 8
Study 29385370 — intervention group
Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel
Number of subjects: 75
Study 29385376 — intervention group
Group type: EXPERIMENTAL
Intervention: 19-28z CAR T cells infusion
Number of subjects: 53
Study 29385399 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium intervention (51.3 mmol sodium/day)
Number of subjects: 99
Study 29385399 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sodium intervention (307.8 mmol sodium/day)
Number of subjects: 99
Study 29385399 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sodium with potassium supplementation (60.0 mmol potassium/day)
Number of subjects: 99
Study 29385444 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral doxycycline (100 mg q12h)
Number of subjects: 200
Study 29385444 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ceftriaxone (2 g q24h)
Number of subjects: 200
Study 29385444 — intervention group
Group type: COMPARATOR
Intervention: Control group (192 subjects without history of Lyme borreliosis)
Number of subjects: 200
Study 29385837 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma biomarker protein panel consisting of 16 proteins
Number of subjects: 545
Study 29385837 — intervention group
Group type: EXPERIMENTAL
Intervention: L-selectin
Number of subjects: 545
Study 29385837 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-like growth factor-binding protein 3
Number of subjects: 545
Study 29385837 — intervention group
Group type: EXPERIMENTAL
Intervention: Coagulation factor X
Number of subjects: 545
Study 29385837 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum paraoxonase/lactonase 3
Number of subjects: 545
Study 29385837 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombospondin-1
Number of subjects: 545
Study 29385837 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronan-binding protein 2
Number of subjects: 545
Study 29385837 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin cofactor 2
Number of subjects: 545
Study 29385837 — intervention group
Group type: EXPERIMENTAL
Intervention: Apolipoprotein B-100
Number of subjects: 545
Study 29385837 — intervention group
Group type: EXPERIMENTAL
Intervention: von Willebrand factor
Number of subjects: 545
Study 29386048 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP changes (5 and 10 cmH2O)
Number of subjects: 14
Study 29386048 — intervention group
Group type: EXPERIMENTAL
Intervention: P-V curve method
Number of subjects: 14
Study 29386048 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical impedance tomography (EIT)
Number of subjects: 14
Study 29386196 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib in combination with R-ICE (rituximab, ifosfamide, carboplatin, etoposide) at 840 mg daily
Number of subjects: 21
Study 29386196 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib in combination with R-ICE
Number of subjects: 21
Study 29386195 — intervention group
Group type: EXPERIMENTAL
Intervention: Galinpepimut-S (multivalent WT1 peptide vaccine) administered as 6 vaccinations over 10 weeks, with potential for 6 additional monthly doses if in CR1.
Number of subjects: 0
Study 29386249 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP-4 inhibitor therapy
Number of subjects: 0
Study 29386274 — intervention group
Group type: EXPERIMENTAL
Intervention: BEEMS (Balance and Eye-Movement Exercises)
Number of subjects: 88
Study 29386274 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 88
Study 29386298 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial and eosinophilic exacerbations
Number of subjects: 101
Study 29386298 — intervention group
Group type: COMPARATOR
Intervention: Viral exacerbations
Number of subjects: 101
Study 29386298 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD phenotypes
Number of subjects: 101
Study 29386411 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 0
Study 29386888 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate-vilanterol
Number of subjects: 229
Study 29386888 — intervention group
Group type: COMPARATOR
Intervention: Vilanterol alone
Number of subjects: 229
Study 29386912 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous tanezumab (2.5, 5, and 10 mg)
Number of subjects: 0
Study 29386912 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous tanezumab (2.5 mg)
Number of subjects: 0
Study 29386912 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous tanezumab (5 mg)
Number of subjects: 0
Study 29386912 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous tanezumab (10 mg)
Number of subjects: 0
Study 29387020 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment-Based Compassion Therapy (ABCT) combined with treatment as usual (TAU)
Number of subjects: 42
Study 29387020 — intervention group
Group type: COMPARATOR
Intervention: Relaxation (active control group) combined with treatment as usual (TAU)
Number of subjects: 42
Study 29387022 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Seizure Therapy (MST)
Number of subjects: 8
Study 29387432 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline suPAR levels
Number of subjects: 411
Study 29387432 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline suPAR levels (adjusted for risk score)
Number of subjects: 411
Study 29387473 — intervention group
Group type: EXPERIMENTAL
Intervention: H5VLP vaccine co-administered with Alhydrogel
Number of subjects: 0
Study 29387473 — intervention group
Group type: EXPERIMENTAL
Intervention: H5VLP vaccine co-administered with GLA-SE
Number of subjects: 0
Study 29387681 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-instruction movement and preliteracy program
Number of subjects: 11
Study 29387682 — intervention group
Group type: EXPERIMENTAL
Intervention: Ride-on car training combined with an adult-directed social interaction program
Number of subjects: 29
Study 29387682 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 29
Study 29388048 — intervention group
Group type: EXPERIMENTAL
Intervention: DrotAA (drotrecogin alfa)
Number of subjects: 2627
Study 29388048 — intervention group
Group type: COMPARATOR
Intervention: Control (nonDrotAA)
Number of subjects: 2627
Study 29388068 — intervention group
Group type: EXPERIMENTAL
Intervention: NSF patients
Number of subjects: 28
Study 29388068 — intervention group
Group type: COMPARATOR
Intervention: ISF patients
Number of subjects: 28
Study 29388068 — intervention group
Group type: EXPERIMENTAL
Intervention: ISF patients with narrow-QRS complexes
Number of subjects: 28
Study 29388068 — intervention group
Group type: EXPERIMENTAL
Intervention: NSF and wide-QRS ISF patients
Number of subjects: 28
Study 29388068 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-QRS ISF patients
Number of subjects: 28
Study 29388336 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal oestradiol
Number of subjects: 0
Study 29388336 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29388385 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Watchers (WW)
Number of subjects: 130
Study 29388385 — intervention group
Group type: COMPARATOR
Intervention: Self-guided control group (SG)
Number of subjects: 130
Study 29388385 — intervention group
Group type: EXPERIMENTAL
Intervention: Both WW and SG
Number of subjects: 130
Study 29388903 — intervention group
Group type: EXPERIMENTAL
Intervention: FGln tracer (mean, 244 MBq ± 118, <100 μg) administered intravenously
Number of subjects: 25
Study 29389078 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% Tapinarof cream
Number of subjects: 11
Study 29389078 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% Tapinarof cream
Number of subjects: 11
Study 29389157 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention with social ties
Number of subjects: 0
Study 29389360 — intervention group
Group type: EXPERIMENTAL
Intervention: hESC-derived cardiovascular progenitors (median dose 8.2 million)
Number of subjects: 6
Study 29389364 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 29389444 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole, ~1.2 mg/kg lean body weight (LBW)
Number of subjects: 41
Study 29389444 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole, LBW dosing
Number of subjects: 41
Study 29390148 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet) adherence (MedDietScore)
Number of subjects: 244
Study 29391051 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 days of high-dose amoxicillin
Number of subjects: 270
Study 29391051 — intervention group
Group type: COMPARATOR
Intervention: 10 days of high-dose amoxicillin (reference standard)
Number of subjects: 270
Study 29391341 — intervention group
Group type: EXPERIMENTAL
Intervention: Unengaged group (n=102)
Number of subjects: 215
Study 29391341 — intervention group
Group type: EXPERIMENTAL
Intervention: MVPA evening peak group (n=108)
Number of subjects: 215
Study 29391374 — intervention group
Group type: EXPERIMENTAL
Intervention: wP (whole-cell pertussis) vaccine as the first vaccine dose
Number of subjects: 500
Study 29391374 — intervention group
Group type: COMPARATOR
Intervention: aP (subunit acellular pertussis) vaccine as the first vaccine dose
Number of subjects: 500
Study 29391382 — intervention group
Group type: EXPERIMENTAL
Intervention: bDMARD treatment
Number of subjects: 3000
Study 29391382 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic, prognostic and predictive biomarkers
Number of subjects: 3000
Study 29391819 — intervention group
Group type: EXPERIMENTAL
Intervention: High flow rate (HFR) at 10.4 mL/s
Number of subjects: 132
Study 29391819 — intervention group
Group type: COMPARATOR
Intervention: Low flow rate (LFR) at 1.7 mL/s
Number of subjects: 132
Study 29391819 — intervention group
Group type: EXPERIMENTAL
Intervention: High flow rate (HFR)
Number of subjects: 132
Study 29391819 — intervention group
Group type: COMPARATOR
Intervention: Low flow rate (LFR)
Number of subjects: 132
Study 29392234 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine lozenges (25 mg) taken up to every 2 hours for 7 days plus standard pain treatment minus topical lidocaine
Number of subjects: 50
Study 29392234 — intervention group
Group type: COMPARATOR
Intervention: Standard pain treatment including topical lidocaine
Number of subjects: 50
Study 29392425 — intervention group
Group type: EXPERIMENTAL
Intervention: Plerixafor plus FLAG-Ida regimen
Number of subjects: 57
Study 29392418 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-L-cysteine (NAC) supplementation (1 g/day)
Number of subjects: 32
Study 29392418 — intervention group
Group type: COMPARATOR
Intervention: Usual diet (UD)
Number of subjects: 32
Study 29392418 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute methionine loading (MetLo) (0.1 g Met/kg mass weight)
Number of subjects: 32
Study 29392450 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous artesunate (IV AS) at a maximum tolerated dose (MTD) of 18 mg/kg
Number of subjects: 19
Study 29392450 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous artesunate (IV AS) at dosages of 12 mg/kg, 18 mg/kg, and 25 mg/kg
Number of subjects: 19
Study 29392736 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition Quality Improvement Program (QIP)
Number of subjects: 2588
Study 29392736 — intervention group
Group type: COMPARATOR
Intervention: Historical controls (medical patients)
Number of subjects: 2588
Study 29393183 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (PCV or temozolomide)
Number of subjects: 0
Study 29393183 — intervention group
Group type: COMPARATOR
Intervention: Irradiation alone
Number of subjects: 0
Study 29393219 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low contrast volume technique for coronary procedures
Number of subjects: 30
Study 29393655 — intervention group
Group type: EXPERIMENTAL
Intervention: 3HP (isoniazid 900 mg + rifapentine 900 mg)
Number of subjects: 126
Study 29393655 — intervention group
Group type: COMPARATOR
Intervention: 9H (isoniazid 300 mg)
Number of subjects: 126
Study 29393655 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (3HP and 9H)
Number of subjects: 126
Study 29393720 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial-challenge-testing (BCT)
Number of subjects: 724
Study 29393720 — intervention group
Group type: EXPERIMENTAL
Intervention: BCT in group A
Number of subjects: 724
Study 29393720 — intervention group
Group type: EXPERIMENTAL
Intervention: BCT in group B
Number of subjects: 724
Study 29393986 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab-bendamustine (chemoimmunotherapy)
Number of subjects: 681
Study 29394124 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide plus low-dose dexamethasone (LoDEX)
Number of subjects: 0
Study 29394124 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29394125 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (anti-PD-1)
Number of subjects: 0
Study 29394251 — intervention group
Group type: EXPERIMENTAL
Intervention: Floatation-REST (1-hour session)
Number of subjects: 50
Study 29394504 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 241
Study 29394504 — intervention group
Group type: COMPARATOR
Intervention: INR thresholds
Number of subjects: 241
Study 29394884 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi intervention (IG, n = 80), 2 lessons per week for 16 weeks, 1 hour per lesson
Number of subjects: 160
Study 29394884 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG, n = 80), no treatment, usual recreational activities
Number of subjects: 160
Study 29394904 — intervention group
Group type: EXPERIMENTAL
Intervention: ORIF with additional wrist arthroscopy
Number of subjects: 50
Study 29394904 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluoroscopic-assisted ORIF
Number of subjects: 50
Study 29394907 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective ventilation strategy (VT set at 6-8 ml/kg, PEEP at 6-8 cmH2O)
Number of subjects: 334
Study 29394907 — intervention group
Group type: COMPARATOR
Intervention: Control group (VT set at 10-12 ml/kg, no PEEP or recruitment maneuvers)
Number of subjects: 334
Study 29394908 — intervention group
Group type: EXPERIMENTAL
Intervention: daily calorie restriction (reduce habitual daily energy intake by 25%)
Number of subjects: 60
Study 29394908 — intervention group
Group type: EXPERIMENTAL
Intervention: intermittent fasting with calorie restriction (alternate between 24-hour periods of fasting and feeding to 150% of habitual daily energy intake)
Number of subjects: 60
Study 29394908 — intervention group
Group type: EXPERIMENTAL
Intervention: intermittent fasting without calorie restriction (alternate between 24-hour periods of fasting and feeding to 200% of habitual daily energy intake)
Number of subjects: 60
Study 29394908 — intervention group
Group type: COMPARATOR
Intervention: Current nutritional interventions for weight management
Number of subjects: 60
Study 29394918 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily co-formulated tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) for up to 24 months; follow-up includes testing for HIV at 1 month, HIV and other sexually transmissible infections three-monthly, HCV annually, and renal function monitoring six-monthly.
Number of subjects: 3700
Study 29394922 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher grip strength (highest tertile)
Number of subjects: 350
Study 29394922 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D sufficiency
Number of subjects: 350
Study 29395172 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (acute and long term use)
Number of subjects: 160
Study 29395172 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid restriction and salt tablets for SIADH
Number of subjects: 160
Study 29395858 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Reappraisal Intervention for Suicide Prevention (CRISP)
Number of subjects: 0
Study 29395863 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks for up to 2 years
Number of subjects: 40
Study 29395863 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 40
Study 29395867 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (platinum-based)
Number of subjects: 1170
Study 29395867 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (taxane)
Number of subjects: 1170
Study 29395867 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrointestinal cancers
Number of subjects: 1170
Study 29395867 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid cancers
Number of subjects: 1170
Study 29395867 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal or cervical surgery
Number of subjects: 1170
Study 29395867 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment during pregnancy
Number of subjects: 1170
Study 29395867 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 1170
Study 29396091 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib, lenalidomide, and rituximab (induction phase: 12 cycles of 28 days; maintenance phase: ibrutinib and rituximab only, cycle duration 56 days)
Number of subjects: 50
Study 29396091 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib, lenalidomide, and rituximab (induction phase)
Number of subjects: 50
Study 29396091 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib, lenalidomide, and rituximab
Number of subjects: 50
Study 29396094 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP (rituximab plus cyclophosphamide [750 mg/m2], doxorubicin, vincristine, and prednisone) followed by radioimmunotherapy and maintenance rituximab for 4 years
Number of subjects: 84
Study 29396094 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP and radioimmunotherapy
Number of subjects: 84
Study 29396094 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab maintenance therapy
Number of subjects: 84
Study 29396094 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall therapeutic strategy (R-CHOP, radioimmunotherapy, and maintenance rituximab)
Number of subjects: 84
Study 29396094 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-related deaths
Number of subjects: 84
Study 29396259 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental supply of alcohol
Number of subjects: 1927
Study 29396259 — intervention group
Group type: EXPERIMENTAL
Intervention: Supply from other sources
Number of subjects: 1927
Study 29396259 — intervention group
Group type: COMPARATOR
Intervention: No supply from any source
Number of subjects: 1927
Study 29396389 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile intervention group (various levels of physician access to patient data)
Number of subjects: 163
Study 29396389 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 163
Study 29396857 — intervention group
Group type: EXPERIMENTAL
Intervention: FLAI-GO induction regimen (fludarabine 30 mg/sqm, cytarabine 2 g/sqm, idarubicin 10 mg/sqm, Gemtuzumab-Ozogamicin 3 mg/sqm)
Number of subjects: 130
Study 29396857 — intervention group
Group type: EXPERIMENTAL
Intervention: FLAI-GO induction regimen
Number of subjects: 130
Study 29397019 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood collection tubes (BCT) (Streck)
Number of subjects: 50
Study 29397019 — intervention group
Group type: COMPARATOR
Intervention: K3EDTA tubes
Number of subjects: 50
Study 29397118 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% oxygen
Number of subjects: 5749
Study 29397118 — intervention group
Group type: COMPARATOR
Intervention: 30% oxygen
Number of subjects: 5749
Study 29397116 — intervention group
Group type: EXPERIMENTAL
Intervention: IVC ultrasound-guided volume management
Number of subjects: 160
Study 29397116 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IVCUS assessment)
Number of subjects: 160
Study 29397119 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon anaesthesia
Number of subjects: 256
Study 29397139 — intervention group
Group type: EXPERIMENTAL
Intervention: Presurgical antiplatelet therapy (APT) prescribed in 95% of procedures; preoperatively discontinued in 15%.
Number of subjects: 432
Study 29397139 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 432
Study 29397139 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 432